[Remote] Director, Medical Affairs – US Hereditary Disease at Illumina

United States

Illumina Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Genomics, HealthcareIndustries

Skills

Key technologies and capabilities for this role

Medical AffairsHereditary DiseaseGenomic TechnologyMolecular GeneticistDiagnostic Genetic TestingNext-Generation SequencingClinical GenomicsScientific EducationProduct DevelopmentRegulatory AffairsBioinformaticsAssay DevelopmentQuality Assurance

Questions & Answers

Common questions about this position

What qualifications are required for the Director, Medical Affairs role?

The role requires a board-certified clinical laboratory molecular geneticist with experience in hereditary disease screening and diagnostic genetic testing, a background in molecular and cytogenetic methods for various hereditary disorders, and a deep understanding of next-generation sequencing, clinical laboratory practices, and regulatory oversight.

Is this a remote position or does it require office work?

This information is not specified in the job description.

What is the salary or compensation for this position?

This information is not specified in the job description.

What is the company culture like at Illumina?

Illumina fosters a culture where every person in every role has the opportunity to make a difference, surrounded by extraordinary people, inspiring leaders, and world-changing projects, enabling employees to do more and become more than they thought possible.

What makes a strong candidate for this Medical Affairs Director position?

A strong candidate has a history of successful impact at clinical genomics laboratories using next-generation sequencing for hereditary disease, experience at the intersection of medical and commercial activities, understanding of US medical genetics trends, and a wide network with key opinion leaders.

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters
1998Year Founded
$27.2MTotal Funding
IPOCompany Stage
Venture Capital, BiotechnologyIndustries
5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.
Standardizing proteomics data across platforms could challenge Illumina's data reliability.
Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.
The company offers innovative array-based solutions for DNA, RNA, and protein analysis.
Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.
Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.
Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI